Sunday, May 14, 2023 1:44:49 PM
I don't remember seeing this slide before. Another strong point for OTLK's approval.
1. High standards
2. Monoclonal Antibody Shearing/Fragmentation During the Repackaging Process (Slide 11)
3. "Extended storage of the drug in the syringe can potentially increase the chance of particle formation, especially in silicone-based systems. Unwanted particles in the solution can cause irritation in the eye and potentially react with the active drug to lower efficacy.¹" (slide 12)
4. "Storage of a protein solution in a plastic syringe can extract leachable material from the syringe barrel and rubber plunger tip. Compounds can induce protein aggregation and potentiate adverse effects in patients such as immunogenicity. Therefore, properly developed therapeutic proteins are not stored in plastic containers." (Slide 13)
Their April presentation has additional info.
https://ir.outlooktherapeutics.com/static-files/e2080eef-8a6b-438b-8447-bf12984db904
Best of luck in your investments!
Recent OTLK News
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
